Citations

Clear

16280 citation(s) found for "Yu, David".

Impact of RAS / BRAF V600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair–Deficient/Microsatellite Instability Colorectal Cancers
Salem, Mohamed E. , Puccini, Alberto , Mauer, Elizabeth , André, Thierry , George, Thomas J. , Tabernero, Josep , Sinicrope, Frank A. , Kopetz, Scott , Cutsem, Eric Van , Overman, Michael J. , Foureau, David , Tie, Jeanne , Kopetz, Scott , Van Cutsem, Eric , Lonardi, Sara , Overman, Michael J , Foureau, David , Mauer, Elizabeth , Sinicrope, Frank A , George, Thomas J , André, Thierry , Tabernero, Josep , Tie, Jeanne , Lonardi, Sara

Mayo Clinic

Clinical Cancer Research | November 14, 2025 | Volume: 32 | Issue: 2 | Pages: 417-427

10.1158/1078-0432.ccr-25-2160 | PMID 41235954 Get It

Abstract Purpose: Routine testing for mismatch repair deficiency (dMMR)/microsatellite instability (MSI) in colorectal cancers is recommended for Lynch syndrome screening, prognosis, and treatment guidance. In the metastatic setting, RAS/BRAF mutations guide treatment decisions. The impact of these mutations on the tumor immune microenvironment (TiME) in MSI/dMMR colorectal cancer is not known. Experimental Design: The study involved retrospective analysis of 448 patients with stage I to IV MSI/dMMR colorectal cancer profiled using next-generation sequencing (Tempus xT DNA sequencing of 595–648 genes at 500x coverage and Tempus xR whole-exome capture RNA sequencing). MSI status was determined by assessing 44 or 239 loci using next-generation sequencing. dMMR was determined using IHC. Tumor mutational burden, tumor neoantigen burden (NTB), PD-L1, immune infiltration, and canonical immune pathways (76 gene set signatures) were analyzed. Results: The median age at diagnosis was 67 years (range, 21–86); 59% of patients were female, and 70% were stage III to IV. Among the 448 patients, 100 (22%) harbored RAS mutations (RASmut), 119 (27%) a BRAFV600E mutation, and 229 (51%) were double wild type. RASmut exhibited lower NTB (median, 12 vs. 15 vs. 16; P = 0.003) and PD-L1 (3.6% vs. 13% vs. 24%; P < 0.001) than BRAFV600E and wild-type tumors, respectively. The RASmut TiME had lower overall inflammation and fewer infiltrating CD8+ T cells than wild-type or BRAFV600E tumors. In contrast, BRAFV600E tumors exhibited hyperproliferative characteristics associated with broad metabolic reprogramming but a similarly inflamed TiME compared with wild-type tumors. Conclusions: Our data suggest that MSI/dMMR colorectal cancers harboring RASmut are less immunogenic, and the TiME contains a lower inflammatory profile than wild-type or BRAFV600E tumors. Further analysis and validation are required to confirm these findings.
One-Year Outcomes of the MODULAR ATP Trial: A Novel Leadless Pacemaker in Wireless Communication With a Subcutaneous Implantable Cardioverter Defibrillator
Lloyd, Michael S. , Roberts, Paul R. , Doshi, Rahul N. , Wright, David J. , Boersma, Lucas V.A. , Friedman, Paul A. , Neužil, Petr , Blomström‐Lundqvist, Carina , Bongiorni, M. G. , Burke, Martin C. , Gras, Daniel , Kutalek, Steven , Marijon, Éloi , Amin, Anish K. , Aasbo, Johan D. , West, Julie, Matznick, Elizabeth , Speakman, Benjamin, Bachman, Tara N. , Reddy, Vivek Y , Roberts, Paul , Doshi, Rahul N , Wright, David L , Boersma, Lucas , Friedman, Paul A , Neuzil, Petr , Blomström-Lundqvist, Carina , Bongiorni, Maria Grazia , Burke, Martin C , Gras, Daniel , Kutalek, Steven P , Marijon, Eloi , Tolosana, Jose María , Amin, Anish K , Epstein, Laurence M , Aasbo, Johan D , Callahan, Thomas D , Brisben, Amy J , Matznick, Elizabeth , Bachman, Tara N , Mont, Lluís , Knops, Reinoud Elwin , Reddy, Vivek Y. , Epstein, Laurence M.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | November 13, 2025 | Volume: 19 | Issue: 1 | Pages: No page available

10.1161/circep.125.014395 | PMID 41231774 Get It

BACKGROUND: MODULAR antitachycardia pacing (ATP), a multicenter, international trial, assesses a modular cardiac rhythm management system: a subcutaneous implantable cardioverter defibrillator in wireless communication with a leadless pacemaker (LP) capable of pace-terminating ventricular tachycardia. METHODS: Enrolees had one or more clinical risk factors for ventricular tachycardia and did not require chronic pacing. Complications included prespecified major LP system- and procedure-related complications, and any complication related to the LP, subcutaneous implantable cardioverter defibrillator, implantation, or study protocol. Survival analysis was performed to identify complication-free rates, therapy delivery, and all-cause mortality. RESULTS: The 297 patients enrolled had an ejection fraction of 35±13%, 43% secondary prevention indications, and 59% with prior ventricular arrhythmias. Of 286 patients undergoing LP implantation (100% success), 251 patients completed 12-month follow-up. Mortality rate was 6%, with none related to the implant procedure. Median follow-up duration was 23.4 months (interquartile range, 17.9–28.1). The LP major complication-free rate was 97.2%, exceeding the performance goal. The overall LP+ subcutaneous implantable cardioverter defibrillator system-related complication-free rate was 88.5%. Appropriate tachyarrhythmia-therapy (ATP+shock) rates were 14.4%, and appropriate shock rates were 8.5%. Inappropriate total tachyarrhythmia therapy was 9.5% of which 8.5% were shocks. ATP was 67.3% successful in terminating ventricular arrhythmia episodes and accelerated ventricular arrhythmias in 10.1% of episodes. Overall therapy burden (ATP+shock) was 96/100 patient-years, of which 44/100 patient-years was for shock delivery. CONCLUSIONS: One-year outcomes of the first modular pacing-defibrillator system reveal low system and LP complication rates and good ATP efficacy rates, suggesting that the modular cardiac rhythm management is a viable alternative to single-chamber implantable cardioverter defibrillators using low-energy pacing capability without the need for transvenous leads. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov/ ; Unique identifier: NCT04798768.
Programmatic Considerations when Scaling Acute Care Telemedicine Services Externally
Fang, Jennifer L. , Schultz, Kelly P., Caples, Sean M., Nestler, David M. , Colby, Christopher E. , Schultz, Kelly, Schultz, Kelly, Demaerschalk, Bart M.

Mayo Clinic

Telemedicine and e-Health | November 13, 2025 | Volume: 32 | Issue: 3 | Pages: 250-255

10.1177/15305627251396572 | PMID 41231085 Get It

After successfully implementing an acute care telemedicine program internally, health care institutions often consider expanding and scaling services externally beyond the initial organizational network. This report outlines important considerations when expanding acute care telemedicine services externally, including cultural alignment and agility, practice context, staffing models, telemedicine technology selection, interrelated services, legal and compliance considerations, quality assurance, risk management, financing, and integration with medical education. These factors may inform program leaders of major planning considerations, potential barriers, and could influence strategic planning. Prospectively identifying and resolving challenges prior to contracting with new external sites will facilitate smooth, successful implementation and high utilization of the acute care telemedicine service.
Troxerutin is a novel osmotic agent for peritoneal dialysis with protective cardiovascular actions
Kopytina, Valeria , Marchant, Vanessa , Rodrigues‐Díez, Raquel , Pascual‐Antón, Lucía , Toggweiler, Nora, Strahl, Lisa, Kane, Jamie , Tejera‐Muñoz, Antonio , Cortés, Marcelino , Sucunza, David , Vaquero, Juan J , Vervloet, Marc G , Eringa, Etto C , Ruiz-Ortega, Marta , López-Cabrera, Manuel , González-Mateo, Guadalupe T , Kane, Jamie , Piecha, Dorothea , Eringa, Etto C.

Mayo Clinic

Nephrology Dialysis Transplantation | November 13, 2025 | Volume: 41 | Issue: 6 | Pages: 1147-1160

10.1093/ndt/gfaf249 | PMID 41231614 Get It

ABSTRACT Background and hypothesis End-stage renal disease patients require peritoneal dialysis (PD) as a life-saving therapy; however, they continue to experience systemic inflammation and increased cardiovascular pathology. These complications can be exacerbated by exposure to PD solutions (PDS) containing glucose. This highlights the clinical unmet need for novel osmotic agents to replace glucose. Here, we tested troxerutin, a Food and Drug Administration–approved drug, as a potential osmotic agent. Methods To evaluate troxerutin osmotic and non-toxic effects, in vitro and in vivo experiments were carried out using artificial membranes, mice and cultured human mesothelial cells (MCs). The local and systemic consequences of chronic peritoneal exposure to PDS associated to renal insufficiency were investigated in a preclinical model. 5/6 nephrectomized C57BL/6J mice were daily exposed to glucose- or troxerutin-PDS for 60 days, then evaluating tissue damage, proinflammatory markers and cardiac damage. Results In vitro and in vivo studies revealed that troxerutin exhibits similar osmotic and ultrafiltration capacities to glucose, but with colloidal properties. Moreover, only glucose, but not troxerutin, reduced MC viability, induced mesothelial-to-mesenchymal transition, and increased damage markers (such as interleukin-6 and vascular endothelial growth factor A). In the preclinical model, long-term treatment with glucose-PDS, but not troxerutin-PDS, significantly increased peritoneal membrane thickening, tissue proinflammatory markers (evaluated in peritoneum, kidney, heart and aorta) and cardiovascular damage (cardiac hypertrophy and fibrosis) in mice. These preclinical data clearly demonstrate the wide deleterious effects of chronic peritoneal exposure to glucose-containing PDS in mice with kidney insufficiency and that the replacement of glucose with troxerutin notably reduces these effects. Conclusion Troxerutin emerges as a more biocompatible alternative to glucose as an osmotic agent for PD therapy, exhibiting no adverse local or systemic side effects in preclinical studies. This research presents a novel approach to reduce cardiovascular complications of PD in end-stage kidney disease.
Cost‐Effectiveness of CT Colonography Under Real‐World Colorectal Cancer Screening Adherence for Black and White Populations
Kao, Szu‐Yu Zoe , Chang, Kevin J. , Moreno, Courtney C. , Brewington, Cecelia , Bruining, David H. , Christensen, Eric , Rula, Elizabeth Y. , Sanelli, Pina C. , Chang, Kevin J , Moreno, Courtney A , Brewington, Cecelia , Christensen, Eric W , Rula, Elizabeth Y , Sanelli, Pina C , Sanmartin, Maria X. , Yee, Judy

Mayo Clinic

Cancer Medicine | November 13, 2025 | Volume: 14 | Issue: 21 | Pages: No page available

10.1002/cam4.71290 | PMID 41229177 Get It

ABSTRACT Background Given the Centers for Medicare and Medicaid Services' coverage of screening CT colonography (CTC) beginning in January 2025, we evaluated the cost‐effectiveness of CTC for colorectal cancer (CRC) screening by race (Black and White) and gender, considering real‐world screening adherence. Methods A microsimulation model compared CRC screening strategies in average‐risk adults by race and gender, incorporating 2010–2019 U.S. data on disease progression and real‐world screening adherence for colonoscopy and fecal immunochemical test (FIT). Five strategies were compared: (1) status quo (choice between colonoscopy and FIT); (2) CTC every 5 years; (3) colonoscopy every 10 years; (4) annual FIT; and (5) multitarget stool DNA test every 3 years, plus no screening. Lifetime costs, quality‐adjusted life years gained (QALYG), and incremental cost‐effectiveness ratios were projected. A willingness‐to‐pay threshold of $100,000/QALYG was used. Results Under the status quo, Black adults showed higher CRC cases and greater utilization for FIT over colonoscopy than White adults. Compared to the status quo, the CTC strategy yielded more QALYG and fewer CRC cases among Black adults, but fewer QALYG and more CRC cases among White adults. Both status quo and CTC strategies outperformed other strategies across races. The CTC strategy was the dominant strategy for Black adults. For White adults, the status quo was cost‐effective with incremental cost‐effectiveness ratios of $34,998–$73,428/QALYG, while the CTC strategy was cost saving compared to no screening. Conclusions CTC could be cost‐effective for CRC screening in Black adults under real‐world screening adherence, supporting Medicare coverage to address specific population needs and structural barriers to screening.
Socioeconomic status and concussion recovery in young athletes
Kreitner, Liga , Crowley, Eric M., Hentz, Roland, Soma, David , Kreitner, Liga A , Hentz, Roland C, Soma, David B, Wi, Chung‐Il

Mayo Clinic

The Physician and Sportsmedicine | November 13, 2025 | Volume: 53 | Issue: 6 | Pages: 500-506

10.1080/00913847.2025.2590420 | PMID 41225295 Get It

Abdominal Arterial Calcification Score‐Association With Patient Survival Post Kidney Transplant
Idilbi, Amro , Ghanem, R, Hanouneh, Tareq, Hassoun, Ali, Nasrini, Tala , Haddad, Walid, Hallak, Mohamed Hussam, Sella, David M., Craver, Emily C. , Alasfar, Sami , Ghanem, Roaa, Alhassoun, Alia, Stegall, Mark D , Schinstock, Carrie , Jarmi, Tambi , Alhassoun, Alia, Alexander, Lauren F. , Stegall, Mark D. , Schinstock, Carrie A. , Jarmi, Tambi

Mayo Clinic

Clinical Transplantation | November 12, 2025 | Volume: 39 | Issue: 11 | Pages: No page available

10.1111/ctr.70387 | PMID 42578517 Get It

ABSTRACT Background Abdominal arterial calcification (AAC) is a common comorbidity in patients with end‐stage kidney disease (ESKD) and a predictor of cardiovascular events post‐kidney transplant. However, prior studies lacked a standardized approach to evaluate AAC and its impact on post‐transplant outcomes. This study aimed to correlate AAC score values with post‐kidney transplant outcomes using a modified scoring system traditionally applied to coronary artery calcification. Methods This retrospective study included 14 339 adult patients listed for kidney transplant between 2002 and 2023 at three transplant centers. Among them, 3683 patients met the criteria of undergoing a kidney transplant and an abdominal computed tomography (CT) scan pre‐transplant. We modified the coronary calcium score software by adjusting intake data points to quantify calcification in the abdominal aorta, common iliac, external iliac, and internal iliac arteries. Outcomes focused on post‐transplant mortality. Results In 3683 kidney transplant recipients, higher AAC scores were significantly associated with increased mortality. Each 1000‐unit increase in AAC score elevated hazard ratios (HRs) across arterial regions, including 1.116 for the aorta and 1.389 for the internal iliac (all p < 0.001). Adjusted analyses confirmed AAC as an independent risk factor for mortality. Kaplan–Meier curves demonstrated lower survival with increasing AAC quartiles. Conclusions AAC, measured by a standardized score, is a significant mortality risk factor in kidney transplant recipients. Integrating AAC scores into pre‐transplant evaluations could enhance risk stratification and improve outcomes. Prospective studies are needed to validate these findings and explore interventions to reduce AAC and improve survival.
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers
Rimini, Margherita , Antonuzzo, Lorenzo , Kim, Jin Won , Saborowski, Anna , Pressiani, Tiziana , Peeters, Frederik , Pircher, Chiara , Parisi, Alessandro , Chon, Hong Jae , Martirena, A. , Fimkelmeier, Fabian, Perkhofer, Lukas , Pinto, C. , KANG, Beodeul , Pastorino, Alessandro , Rodriquenz, Maria Grazia , Scartozzi, Mario, Zumstein, Lucrezia , Ghidini, Michele , Aprile, Giuseppe , Spinelli, Gian Paolo , Yung‐Yeh, Su, Warmington, Emily , Lancianese, Alessia , Lavacchi, Daniele, Vogel, Arndt, Salani, Francesca , Persano, Mara , Balsano, Rita , Passeri, Laura , Satake, Tomoyuki, Rimassa, Lorenza , Casadei‐Gardini, Andrea , Vogel, Arndt , Rapposelli, Ilario Giovanni , Pircher, Chiara , Castet, Florian , Jae Chon, Hong , Landriscina, Matteo , Fenocchio, Elisabetta , Yoo, Changhoon , Kang, Minsu , Persano, Mara , Niger, Monica , Antonuzzo, Lorenzo , Parisi, Alessandro , Casadei-Gardini, Andrea , Rimassa, Lorenza , Casadei-Gardini, Andrea , Saborowski, Anna , Pressiani, Tiziana , Salani, Francesca , Vogel, Arndt , Rimini, Margherita , Fornaro, Lorenzo , Ikeda, Masafumi , Abidoye, Oluseyi , Lucchetti, Jessica , Nichetti, Federico , Vivaldi, Caterina , Braconi, Chiara , Pinato, David J. , Tamburini, Emiliano , Tamberi, Stefano , Castet, Florian , Verrico, Monica , Couto, Nuno , Lamarca, Angela , Oneda, Ester , Avallone, Antonio , Dell’Aquila, Emanuela , Kim, Il Hwan , Garajova, Ingrid , Kang, Beodeul, Corallo, Salvatore , Farinea, Giovanni , Diana, Anna , Schirripa, Marta , Scartozzi, Mario , Prager, Gerald W. , Chan, Stephen L. , Bekaii‐Saab, Tanios , Lonardi, Sara , Prete, Alessandra Anna , Bozzarelli, Silvia , Masi, Gianluca , Niger, Monica , Camera, Silvia , Ferrara, Michele

Mayo Clinic

Liver International | November 12, 2025 | Volume: 45 | Issue: 12 | Pages: No page available

10.1111/liv.70428 | PMID 41221651 Get It

ABSTRACT Background We recently published the first real‐world multicenter and multi‐institutional study of cisplatin, gemcitabine, and durvalumab in patients with advanced biliary tract cancer (BTC). Here we present an expanded patient cohort with an increased sample size and longer median follow‐up. Methods The study population included patients with advanced BTC, who received cisplatin/gemcitabine plus durvalumab at 55 centers across 12 countries in Europe, the United States, and Asia. The primary endpoints of the study were progression‐free survival (PFS) and overall survival (OS). Secondary endpoints were overall response rate (ORR) and safety. Results Overall, 1358 patients were enrolled. Median PFS was 7.6 months (95% CI: 7.2–8.1), and median OS was 15.6 months (95% CI: 14.8–16.5). ORR was 35.6%, and DCR was 82.7%. Any grade AEs occurred in 1213 patients (89.3%). Grade 3–4 AEs occurred in 597 patients (43.2%). The rate of immune‐related AEs (irAE) was 20.3%. Grade 3–4 irAE occurred in 3.0% of patients. At the multivariate analysis for OS, normal albumin level (HR 0.68, 95% CI 0.57–0.81, p < 0.0001), CEA levels within normal ranges (HR 0.68, 95% CI 0.57–0.82, p < 0.0001), NLR < 3 (HR 0.62, 95% CI 0.52–0.74, p < 0.0001), ECOG PS 0 (HR 0.51, 95% CI 0.42–0.61, p < 0.0001), and prior surgery (HR 0.80, 95% CI 0.65–0.99, p = 0.036) were positive prognostic factors. Conclusion The updated findings, derived from an expanded cohort, further support the adoption of durvalumab in combination with gemcitabine and cisplatin in routine clinical practice, reinforcing the efficacy and safety outcomes demonstrated in the phase III TOPAZ‐1 trial.
Gender-Based Differences in Patient Satisfaction With Telemedicine Visits
Vegunta, Suneela , David, Paru S., Khan, Saira , Al-Badri, Mina , Al-Badri, Mina M, Kling, Juliana M.

Mayo Clinic

Journal of Women's Health | November 12, 2025 | Volume: 35 | Issue: 3 | Pages: 318-324

10.1177/15409996251394812 | PMID 41250798 Get It

Objective: Telemedicine addresses limitations in patient access, health care costs, and time spent by patients for health care visits. However, gender-based differences in patient satisfaction with this method are unclear. Our study aimed to evaluate gender-based differences in patient satisfaction for telemedicine (both video and telephone) and in-person health care visits. Methods: Patients were randomly selected to complete a patient satisfaction survey regarding their health care experiences after outpatient medical appointments at a large academic institution. Results: Of 476,777 total respondents, most patients were women (47.5%) and men (37.3%), with fewer patients in the categories transgender, other, or unknown/choose not to disclose (15.2%). Women and men were both satisfied with telemedicine by video or telephone (83.3% women versus 84.5% men rated their visit 5/5) and in-person visits (84.1% women versus 85.7% men rated their visit 5/5). Conclusions: Men and women were nearly equally satisfied with telemedicine and in-person visits, although both genders were slightly less satisfied with telemedicine video visits than in-person visits. The findings indicate that the ongoing integration of telemedicine into clinical practice could serve as a satisfactory alternative to in-person consultations for all patients.